Tevogen Bio Inc. (TVGN)
1.10
-0.10 (-8.33%)
At close: Mar 31, 2025, 3:59 PM
Company Description
Tevogen Bio Holdings Inc. operates as a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology, and neurology.
Its lead investigational precision T cell product, TVGN 489, is designed to address the unmet need of acute-risk COVID-19 patients, as well as a subset of patients suffering from long COVID.
The company is based in Warren, New Jersey.
Tevogen Bio Inc.

Country | United States |
IPO Date | Jan 5, 2022 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 17 |
CEO | Dr. Ryan H. Saadi M.D., M.P.H, M.P.H. |
Contact Details
Address: 15 Independence Blvd Warren, New Jersey United States | |
Website | https://tevogen.com |
Stock Details
Ticker Symbol | TVGN |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001860871 |
CUSIP Number | 88165K101 |
ISIN Number | US88165K1016 |
Employer ID | 98-1597194 |
SIC Code | 6770 |
Key Executives
Name | Position |
---|---|
Dr. Ryan H. Saadi M.D., M.P.H, M.P.H. | Co-Founder, Chief Executive Officer & Chairman |
Kirti Desai CPA | Chief Financial Officer |
Mittul Mehta | Chief Information Officer & Head of Tevogen.ai |
Dr. Neal Flomenberg M.D. | Chief Scientific Officer and Global R&D Lead |
Sadiq Khan M.B.A. | Chief Commercial Officer |
Stephen Chen M.B.A. | Chief Technical Officer |
Tapan V. Shah | Head of Investor Relations & Corporate Development |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 14, 2025 | 4 | Filing |
Mar 11, 2025 | 4 | Filing |
Mar 06, 2025 | 4 | Filing |
Jan 28, 2025 | 424B3 | Filing |
Jan 28, 2025 | 8-K | Current Report |
Dec 26, 2024 | 4 | Filing |
Dec 26, 2024 | 4 | Filing |
Dec 26, 2024 | 4 | Filing |
Dec 26, 2024 | 4 | Filing |
Dec 26, 2024 | 4 | Filing |